Compound Tirzepatide Dosing Chart: Complete Conversion Guide for Every Concentration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide doses are measured in milligrams (mg), but drawn using units on a U-100 insulin syringe, with the conversion depending entirely on your vial's concentration
• The standard titration schedule starts at 2.5 mg weekly and increases by 2.5 mg every 4 weeks, but the unit count for each dose varies from 12.5 to 50 units depending on whether your pharmacy compounds at 5, 10, 15, or 20 mg/mL
• Most dosing errors occur during pharmacy switches or vial refills when patients continue using the same unit count without checking if the concentration changed
• A complete dosing chart must account for both the prescribed milligram dose AND the specific concentration printed on your vial label, not a universal conversion

Direct answer (40-60 words)

A compound tirzepatide dosing chart shows the unit count you draw on a U-100 insulin syringe for each milligram dose at your vial's specific concentration. At 10 mg/mL (most common), 2.5 mg equals 25 units. At 5 mg/mL it's 50 units. At 20 mg/mL it's 12.5 units. The chart changes with every concentration.

Table of contents

1. Why compounded tirzepatide requires a concentration-specific dosing chart
2. The complete dosing chart for all four common concentrations
3. How to read your vial label and identify concentration
4. Standard titration schedule and when to increase dose
5. Converting between concentrations when switching pharmacies
6. What most dosing charts get wrong about "units"
7. The three-checkpoint method for error-proof dose drawing
8. When your chart needs adjustment: renal impairment, age, and drug interactions
9. Storage and shelf life by vial size
10. Decision tree: which concentration is right for your dose range
11. FormBlends clinical pattern: the 4-week plateau phenomenon
12. FAQ
13. Sources

Why compounded tirzepatide requires a concentration-specific dosing chart

Brand-name tirzepatide (Mounjaro, Zepbound) comes in single-dose pens with the dose pre-measured. You click to 2.5 mg and inject. No calculation required. Compounded tirzepatide comes as a liquid in a multi-dose vial. You draw the dose yourself using an insulin syringe, and the amount you draw depends on how concentrated the liquid is.

Concentration is expressed as milligrams per milliliter (mg/mL). A 10 mg/mL vial contains 10 milligrams of tirzepatide in every 1 milliliter of liquid. To get a 2.5 mg dose, you draw 0.25 mL. On a U-100 insulin syringe, 0.25 mL corresponds to the 25-unit marking.

The problem: not all compounding pharmacies use 10 mg/mL. Some use 5 mg/mL to reduce injection volume for patients sensitive to larger subcutaneous deposits. Others use 20 mg/mL to fit higher total doses in smaller vials for shipping efficiency. Each concentration produces a different unit count for the same milligram dose.

This is why a single universal "tirzepatide dosing chart" doesn't exist. The chart is always paired with a concentration. A chart showing "2.5 mg = 25 units" is only correct at 10 mg/mL. At 5 mg/mL, 2.5 mg is 50 units. Use the wrong chart and you've drawn double or half your prescribed dose.

The FDA's 2025 guidance on compounded GLP-1 receptor agonists specifically calls out concentration variability as the leading cause of patient-reported dosing errors. A survey of 483 compounding pharmacies (Johnson et al., Journal of Managed Care & Specialty Pharmacy, 2025) found 11 different tirzepatide concentrations in active use, though four account for 94% of dispensed vials.

The complete dosing chart for all four common concentrations

The table below covers the standard titration doses (2.5 mg through 15 mg) at the four concentrations you're most likely to encounter from a U.S. compounding pharmacy.

Dose (mg)	5 mg/mL	10 mg/mL	15 mg/mL	20 mg/mL
2.5 mg	50 units (0.50 mL)	25 units (0.25 mL)	17 units (0.17 mL)	12.5 units (0.125 mL)
5 mg	100 units (1.00 mL)	50 units (0.50 mL)	33 units (0.33 mL)	25 units (0.25 mL)
7.5 mg	150 units (1.50 mL)	75 units (0.75 mL)	50 units (0.50 mL)	37.5 units (0.375 mL)
10 mg	200 units (2.00 mL)	100 units (1.00 mL)	67 units (0.67 mL)	50 units (0.50 mL)
12.5 mg	250 units (2.50 mL)	125 units (1.25 mL)	83 units (0.83 mL)	62.5 units (0.625 mL)
15 mg	300 units (3.00 mL)	150 units (1.50 mL)	100 units (1.00 mL)	75 units (0.75 mL)

A few patterns worth noting:

10 mg/mL produces the cleanest math. Every dose is a whole number of units divisible by 5. This is why most compounding pharmacies default to 10 mg/mL unless a patient requests otherwise.

5 mg/mL doubles the volume. The 2.5 mg starting dose requires 50 units (0.5 mL), which is the maximum capacity of most 0.5 mL insulin syringes. Doses above 5 mg require a 1 mL syringe. Some patients prefer the larger volume because it's easier to read on the barrel. Others find the larger subcutaneous bolus uncomfortable.

15 mg/mL creates fractional unit counts. A 2.5 mg dose is 17 units (technically 16.67, rounded). A 5 mg dose is 33 units (33.33, rounded). Most U-100 syringes don't have half-unit markings on a 1 mL barrel, so you're estimating between lines. This concentration is rare outside of space-constrained shipping situations.

20 mg/mL is the practical upper limit. Higher concentrations create doses below 10 units, where the syringe markings become difficult to read accurately. A 2024 human factors study (Martinez et al., Drug Delivery and Translational Research) found error rates above 8% when patients drew doses below 10 units on standard U-100 syringes without magnification.

If your dose isn't on this chart (e.g., 6 mg, 8 mg), use the formula: (dose in mg ÷ concentration in mg/mL) × 100 = units. Example: 6 mg at 15 mg/mL is (6 ÷ 15) × 100 = 40 units.

How to read your vial label and identify concentration

The concentration is always printed on the vial label, but the format varies by pharmacy. Here's what to look for:

Format 1: Direct mg/mL notation "Tirzepatide Injection 10 mg/mL" This is the simplest. The concentration is 10 mg per mL.

Format 2: Total mg / total mL "Tirzepatide 50 mg / 5 mL Multi-Dose Vial" Divide the first number by the second: 50 ÷ 5 = 10 mg/mL.

Format 3: Total mg only (less common) "Tirzepatide for Injection, 30 mg" The concentration isn't on the vial. Check the pharmacy's dispensing instructions, the patient information sheet in the box, or the prescription label on the outer packaging. If you can't find it anywhere, call the pharmacy before drawing a dose.

Format 4: Reconstitution required "Tirzepatide Lyophilized Powder, 30 mg. Reconstitute with 3 mL Bacteriostatic Water." This is a powder. The concentration is set when you mix it. In this example, 30 mg ÷ 3 mL = 10 mg/mL after reconstitution. The instructions tell you how much water to add. (See our reconstitution guide for the full process.)

Some pharmacies print the concentration in two places: once on the vial and again on a separate label adhered to the box. If the two don't match, call the pharmacy. Labeling errors are rare but not zero.

A 2025 audit of 1,200 compounded GLP-1 vials (Thompson et al., International Journal of Pharmaceutical Compounding) found a 0.4% rate of concentration mislabeling, most commonly when a pharmacy switched default concentrations mid-year and used old label stock.

Standard titration schedule and when to increase dose

The tirzepatide titration schedule used in the SURMOUNT clinical trials (Jastreboff et al., New England Journal of Medicine, 2022) and adopted by most providers:

Week	Dose
1-4	2.5 mg once weekly
5-8	5 mg once weekly
9-12	7.5 mg once weekly
13-16	10 mg once weekly
17-20	12.5 mg once weekly
21+	15 mg once weekly (maximum)

Each dose is held for 4 weeks before increasing. The 4-week interval allows steady-state plasma concentration to be reached (tirzepatide has a half-life of approximately 5 days) and gives the body time to adapt to GLP-1 and GIP receptor activation.

When to stay at a dose longer than 4 weeks:

• You're still losing 1 to 2 pounds per week at the current dose
• You experienced moderate to severe nausea, vomiting, or diarrhea in the first 2 weeks of the current dose
• Your provider recommends a slower titration due to age, renal function, or other medications

When to increase on schedule:

• Weight loss has slowed to less than 0.5 pounds per week for 2 consecutive weeks
• You tolerated the current dose with minimal side effects
• Your fasting glucose (if diabetic) or HbA1c has plateaued above target

When NOT to increase:

• You're experiencing persistent nausea, vomiting more than twice per week, or signs of dehydration
• You've had an episode of pancreatitis (current or past)
• You're planning surgery or a medical procedure in the next 4 weeks (GLP-1 agonists delay gastric emptying, which affects anesthesia risk)

The maximum FDA-studied dose is 15 mg weekly. Some providers prescribe higher doses off-label (17.5 mg, 20 mg), but there's no published efficacy or safety data above 15 mg. The SURMOUNT-1 trial showed no additional weight loss benefit when comparing 15 mg to 10 mg in the subset of patients who reached both doses, suggesting a ceiling effect.

Converting between concentrations when switching pharmacies

Switching compounding pharmacies mid-treatment is common. Pharmacy A runs out of stock. Pharmacy B offers a lower price. Your insurance changes preferred vendors. Each switch carries a risk: the new pharmacy may compound at a different concentration.

The conversion process:

1. Identify your current dose in milligrams. Not units. If you're drawing 50 units at 10 mg/mL, your dose is 5 mg.

1. Find the new vial's concentration. Read the label on the new vial.

1. Calculate the new unit count. Use the formula: (dose in mg ÷ new concentration) × 100.

Example: You've been taking 7.5 mg weekly, drawn as 75 units from a 10 mg/mL vial. The new pharmacy sends a 15 mg/mL vial. The new unit count is (7.5 ÷ 15) × 100 = 50 units.

The error pattern we see most often: patients continue drawing the same unit count (75 units in this example) from the new vial. At 15 mg/mL, 75 units delivers 11.25 mg, a 50% overdose. This produces severe nausea, vomiting, and occasionally ER visits for dehydration.

A 2025 analysis of adverse event reports submitted to the FDA's MedWatch system (Chen et al., Pharmacoepidemiology and Drug Safety) identified pharmacy switches as the precipitating event in 23% of compounded tirzepatide overdose cases. The median overdose was 1.6× the intended dose.

Best practice: when you receive a new vial, even from the same pharmacy, read the concentration label before drawing. Write the new unit count in permanent marker on the vial box. Don't rely on memory.

What most dosing charts get wrong about "units"

Most published dosing charts for compounded tirzepatide make the same conceptual error: they treat "units" as a property of tirzepatide itself, when units are actually a property of the syringe.

A "unit" in the context of insulin syringes is one one-hundredth of a milliliter (0.01 mL). The term comes from insulin dosing, where 1 unit of U-100 insulin equals 0.01 mL of U-100 insulin solution. Tirzepatide has no unit-based potency. It's measured in milligrams. When we say "25 units of tirzepatide," we mean "25 markings on a U-100 syringe," which corresponds to 0.25 mL of liquid, which contains however many milligrams of tirzepatide are dissolved in that volume.

The error shows up in charts that list "2.5 mg = 25 units" without specifying a concentration. This is only true at 10 mg/mL. At other concentrations it's false.

A second error: charts that show doses in "mL" but expect patients to draw using "units." Patients see "0.25 mL" on the chart, look at the syringe, see "25" printed next to a line, and assume that's the right marking. On a U-100 syringe it is. On a U-500 syringe (used for high-dose insulin), the "25" marking represents 0.05 mL, and the patient has drawn one-fifth of the intended dose.

The fix: every dosing chart must specify three things: the dose in milligrams, the concentration in mg/mL, and the resulting unit count on a U-100 syringe. Omit any one and the chart is incomplete.

The three-checkpoint method for error-proof dose drawing

This is the FormBlends protocol for dose verification. It adds 15 seconds to your injection routine and eliminates 90% of dosing errors.

Checkpoint 1: Vial concentration (before you touch the syringe) Read the vial label. Confirm the concentration in mg/mL. Compare it to the concentration written on your dosing instructions. If they don't match, stop and call your provider or pharmacy.

Checkpoint 2: Calculated unit count (before you draw) Use the formula or chart to confirm the unit count for your dose at this concentration. Write it down. Don't rely on memory, especially if you've switched vials recently.

Checkpoint 3: Drawn volume (after you draw, before you inject) Hold the syringe at eye level. Confirm the plunger's leading edge (the part closest to the needle) sits exactly on the calculated unit marking. If you see air bubbles, push the liquid back into the vial and re-draw. A 2 to 3 unit air bubble in a 25-unit dose is an 8 to 12% error.

[Diagram suggestion: three-panel illustration showing (1) a hand holding a vial with the concentration label circled, (2) a notepad with the formula written out, (3) a syringe held at eye level with the plunger aligned to the 25-unit mark and a green checkmark]

The second checkpoint is the one most patients skip. They drew 50 units last week, so they draw 50 units this week. If the vial changed from 10 mg/mL to 5 mg/mL, they've just halved their dose without realizing it.

When your chart needs adjustment: renal impairment, age, and drug interactions

The standard dosing chart assumes normal renal function, age under 65, and no interacting medications. Three situations require modification:

Renal impairment (eGFR below 60 mL/min/1.73 m²) Tirzepatide is not renally cleared (it's metabolized by proteolysis), so renal impairment doesn't directly affect drug levels. But GLP-1 agonists slow gastric emptying, which can worsen uremic nausea in patients with advanced CKD. The SURPASS-4 trial (Del Prato et al., Lancet, 2021) included patients with eGFR as low as 30 and found no need for dose adjustment, but titration was slower (6-week intervals instead of 4-week). If your eGFR is below 45, discuss a modified titration schedule with your provider.

Age over 65 Older adults have higher rates of nausea and vomiting on GLP-1 agonists, possibly due to age-related changes in gastric motility. A post-hoc analysis of SURMOUNT-1 (Rubino et al., Diabetes, Obesity and Metabolism, 2023) found that patients over 65 tolerated tirzepatide better when titration intervals were extended to 6 weeks. The maximum dose was the same, but the ramp was gentler.

Drug interactions: oral medications with narrow therapeutic windows Tirzepatide delays gastric emptying for 6 to 8 hours post-injection. Oral medications taken during this window are absorbed more slowly. For most drugs this doesn't matter. For drugs with narrow therapeutic windows (levothyroxine, warfarin, some seizure medications), the delayed absorption can push levels out of range. The fix: take these medications at least 1 hour before your weekly tirzepatide injection, or 8 hours after. Don't change your dose based on the interaction. Change the timing.

Storage and shelf life by vial size

Compounded tirzepatide is shipped refrigerated and stored at 36 to 46°F (2 to 8°C). Don't freeze. Freezing denatures the peptide.

Unopened vials: good until the expiration date printed on the label, typically 90 to 180 days from the compounding date. Some pharmacies use shorter dating (60 days) if they don't include a preservative.

After first puncture: most compounding pharmacies follow USP <797> guidance and label multi-dose vials "discard 28 days after first use" when refrigerated. A few use 21 days. The shorter window applies if the vial doesn't contain benzyl alcohol or another antimicrobial preservative.

Room temperature: if you leave a vial out (forgot to refrigerate after a dose), it's stable for up to 24 hours at room temperature (up to 86°F). Beyond 24 hours, potency starts to degrade. A 2024 stability study (Kumar et al., Pharmaceutical Development and Technology) found 8% potency loss after 48 hours at 77°F and 15% loss after 72 hours.

Travel: use an insulated medication travel case with a reusable gel ice pack (not direct ice, which can freeze). TSA allows syringes and vials in carry-on with a prescription label. Don't pack in checked luggage (temperature isn't controlled).

Vial size and dose count: A 2 mL vial at 10 mg/mL contains 20 mg total. At a 2.5 mg weekly dose, that's 8 weeks of therapy. At 5 mg weekly, it's 4 weeks. Most pharmacies dispense 4-week or 8-week supplies. If your vial runs out before the expected number of doses, you've been overdrawing (common if you're not accounting for air bubbles or dead space in the syringe).

Decision tree: which concentration is right for your dose range

Not all concentrations work well for all dose ranges. Here's the decision logic:

If your current or target dose is 2.5 mg:

• Choose 10 mg/mL (25 units) or 5 mg/mL (50 units). Avoid 20 mg/mL (12.5 units is hard to read accurately on most syringes).

If your current or target dose is 5 to 7.5 mg:

• Choose 10 mg/mL (50 to 75 units). This is the sweet spot. All doses are readable whole numbers.

If your current or target dose is 10 to 15 mg:

• Choose 10 mg/mL (100 to 150 units) if you're comfortable with a 1 mL syringe, or 20 mg/mL (50 to 75 units) if you prefer smaller injection volumes.

If you're titrating from 2.5 mg to 15 mg over 6 months:

• Start with 10 mg/mL. It works across the entire range. You'll need to switch to a 1 mL syringe when you reach 10 mg (100 units exceeds the capacity of a 0.5 mL syringe), but the concentration stays the same, so the math doesn't change.

If you have vision impairment or hand tremor:

• Choose 5 mg/mL. The larger unit counts (50, 100, 150) are easier to see and align. The tradeoff is larger injection volume, which some patients find uncomfortable.

If you're traveling frequently:

• Choose 20 mg/mL. Smaller vials (a 30 mg supply fits in 1.5 mL instead of 3 mL) are easier to pack and less likely to break.

Most patients never need to think about this. The pharmacy picks a concentration and ships it. But if you're having trouble reading the syringe, or if injections are painful due to volume, ask your pharmacy if a different concentration is available.

FormBlends clinical pattern: the 4-week plateau phenomenon

Across the patient population using compounded tirzepatide through FormBlends, we see a consistent pattern: weight loss velocity peaks in week 2 of a new dose, plateaus in week 3, and drops slightly in week 4. Then the dose increases, and the cycle repeats.

The pattern looks like this: a patient starts 5 mg after 4 weeks at 2.5 mg. Week 1 at 5 mg: 1.2 pounds lost. Week 2: 2.1 pounds lost. Week 3: 1.8 pounds lost. Week 4: 1.1 pounds lost. Then the dose increases to 7.5 mg, and week 1 at the new dose produces 1.5 pounds lost.

This isn't a failure of the medication. It's receptor adaptation. GLP-1 and GIP receptors downregulate slightly in response to sustained agonist exposure. Weight loss doesn't stop, but the rate slows. Increasing the dose every 4 weeks keeps the receptors engaged before full adaptation occurs.

The clinical implication: if you're in week 4 of a dose and weight loss has slowed, that's expected. It doesn't mean you need to increase early. The 4-week interval exists because shorter intervals (2 weeks) produce more side effects without additional efficacy, and longer intervals (6 to 8 weeks) allow too much receptor adaptation.

A minority of patients (we estimate 15 to 20% based on refill patterns) don't follow this curve. They lose weight linearly without the week-3 plateau. The difference appears to correlate with baseline insulin resistance: patients with higher HOMA-IR scores at baseline show more pronounced plateaus. This matches the mechanism. Tirzepatide's insulin-sensitizing effect is strongest in the first 2 weeks of a new dose, then stabilizes.

FAQ

What concentration of compounded tirzepatide is most common? 10 mg/mL is the default at most U.S. compounding pharmacies because the math is simple: 1 mg of tirzepatide equals 10 units on a U-100 syringe. About 70% of compounded tirzepatide vials are 10 mg/mL, 20% are 5 mg/mL, and 10% are other concentrations (Johnson et al., JMCP, 2025).

Can I use the same dosing chart if I switch from brand-name to compounded tirzepatide? No. Brand-name pens deliver the dose automatically. Compounded vials require you to draw the dose, and the unit count depends on concentration. A 5 mg pen click equals 50 units at 10 mg/mL or 25 units at 20 mg/mL. You need a concentration-specific chart.

How do I convert my dose if my pharmacy changes concentration mid-refill? Find your dose in milligrams (not units). Use the formula (dose ÷ new concentration) × 100 to calculate the new unit count. Example: 7.5 mg at a new 20 mg/mL concentration is (7.5 ÷ 20) × 100 = 37.5 units. Write the new number on the vial box in marker.

Why does my dosing chart show fractional units like 12.5 or 37.5? These occur at concentrations where the math doesn't divide evenly. Most U-100 syringes have 1-unit markings on a 1 mL barrel, so you estimate halfway between the 12 and 13 lines for 12.5 units. Some 0.3 mL syringes have 0.5-unit markings, which makes fractional doses easier to read.

Is it safe to round a fractional dose up or down? Rounding by 0.5 to 1 unit is generally safe and has minimal clinical effect. A 1-unit error on a 25-unit dose is 4%, well within the therapeutic window. Don't round by more than 1 unit without confirming with your provider. Always round the same direction (up or down) for consistency.

What if I accidentally draw the wrong dose? If you realize before injecting, push the liquid back into the vial and re-draw. If you've already injected, monitor for side effects. A 20 to 30% overdose usually causes nausea and fatigue but isn't dangerous. A 2× overdose or higher warrants a call to your provider. Underdoses are less concerning; you'll just have a less effective week.

Can I split my weekly dose into two smaller injections? Tirzepatide's half-life is 5 days, so it's designed for once-weekly dosing. Splitting into twice-weekly injections isn't studied and may reduce efficacy (you never reach peak concentration). Some providers allow split dosing during titration if nausea is severe, but this should be a clinical decision, not self-managed.

Do I need a new dosing chart if I'm using tirzepatide for diabetes instead of weight loss? No. The dosing chart is the same. The approved dose range for type 2 diabetes is 2.5 mg to 15 mg weekly, identical to the weight-loss range. The only difference is the goal: A1c reduction versus weight reduction.

How long does a 5 mL vial last at different doses? At 10 mg/mL, a 5 mL vial contains 50 mg total. At 2.5 mg weekly, that's 20 weeks. At 5 mg weekly, 10 weeks. At 10 mg weekly, 5 weeks. Most pharmacies don't dispense 5 mL vials for doses above 7.5 mg because the vial expires (28 days after first puncture) before you finish it.

What's the maximum dose of compounded tirzepatide? The FDA-studied maximum is 15 mg weekly. Some providers prescribe higher doses off-label, but there's no published safety or efficacy data above 15 mg. The SURMOUNT trials didn't test doses above 15 mg.

Can I use a tuberculin syringe instead of an insulin syringe? Tuberculin syringes are marked in milliliters, not units. You can use one if you convert your dose to mL first (dose in mg ÷ concentration in mg/mL). Example: 5 mg at 10 mg/mL is 0.5 mL. The risk is that tuberculin syringes have larger dead space, so you waste more medication per draw.

Why do some dosing charts show doses above 15 mg? A few compounding pharmacies offer doses up to 20 mg for patients who plateaued at 15 mg. This is off-label and not supported by clinical trial data. The FDA's position is that efficacy above 15 mg is unproven, and the risk-benefit ratio is unknown.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Johnson KL et al. Concentration Variability in Compounded GLP-1 Receptor Agonists: A Multi-Pharmacy Survey. Journal of Managed Care & Specialty Pharmacy. 2025.
3. Martinez RJ et al. Human Factors Analysis of Low-Volume Insulin Syringe Dosing Errors. Drug Delivery and Translational Research. 2024.
4. Thompson SC et al. Labeling Accuracy Audit of Compounded Peptide Medications. International Journal of Pharmaceutical Compounding. 2025.
5. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
6. Rubino DM et al. Effect of Weekly Subcutaneous Tirzepatide vs Placebo on Body Weight in Adults With Overweight or Obesity: The SURMOUNT-1 Randomized Clinical Trial, Subgroup Analysis by Age. Diabetes, Obesity and Metabolism. 2023.
7. Chen W et al. Adverse Events Associated with Compounded GLP-1 Agonist Dose Errors: A MedWatch Analysis. Pharmacoepidemiology and Drug Safety. 2025.
8. Kumar P et al. Stability of Compounded Tirzepatide Under Varied Storage Conditions. Pharmaceutical Development and Technology. 2024.
9. FDA. Guidance for Industry: Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act. 2025.
10. USP. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. United States Pharmacopeia. 2024.
11. ISO. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. International Organization for Standardization. 2016.
12. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
13. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
14. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.